Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma
Overview
Oncology
Authors
Affiliations
Tumors expressing programmed death ligand 1 (PD-L1) interact with the corresponding negative-signal generating immune receptor on the surface of CD8 T cells, PD-1, thereby suppressing antitumor activity. Therapeutics blocking this interaction have shown promise in various cancers by restoring functional antitumor T-cell activity. We explored the degree of PD-L1, PD-1, and CD8 expression in a retrospective analysis of 29 clinical synovial sarcoma samples. Quantitative immunohistochemistry and multiplex immunofluorescence were used to determine relative quantification of CD8 and PD-1 T cells and PD-L1 expression within the intratumor area and the interface between the tumor and the surrounding nontumor tissue (i.e., invasive margin), and colocalization of these factors, respectively. PD-L1, PD-1, and CD8 cell densities in the tumor-invasive margins were significantly higher in the metastatic tumors than the primary tumors (P < 0.01), and PD-L1, PD-1, and CD8 cell densities were all significantly positively correlated with one other (P < 0.0001). PD-1 cell density in the tumor-invasive margin was significantly associated with worse progression-free survival. Multiplex immunofluorescence demonstrated coexpression of PD-1 and CD8 on lymphocytes within the invasive margin, as well as relative proximity between PD-1 CD8 cells and PD-L1 tumor cells. Our results provide a preclinical rationale for screening of patients with synovial sarcoma for the colocalization of CD8, PD-1, and PD-L1, which may be a marker for response to PD-1 blockade therapy. Cancer Immunol Res; 5(2); 118-26. ©2016 AACR.
PD‑1/PD‑L1 immune checkpoint in bone and soft tissue tumors (Review).
Hashimoto K, Nishimura S, Goto K Mol Clin Oncol. 2025; 22(4):31.
PMID: 39989606 PMC: 11843085. DOI: 10.3892/mco.2025.2826.
Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer.
Qu F, Wu S, Yu W Onco Targets Ther. 2024; 17:1223-1253.
PMID: 39735789 PMC: 11681808. DOI: 10.2147/OTT.S500281.
Luk S, IJsselsteijn M, Somarakis A, Acem I, de Bruijn I, Szuhai K Cancer Immunol Immunother. 2024; 74(1):31.
PMID: 39708175 PMC: 11663204. DOI: 10.1007/s00262-024-03868-2.
Xu N, Xie K, Xin D, Liang Z, Zeng Y J Cancer Res Clin Oncol. 2024; 150(8):392.
PMID: 39162837 PMC: 11335867. DOI: 10.1007/s00432-024-05852-w.
Haq A, Yang P, Jin C, Shih J, Chen L, Tseng H Theranostics. 2024; 14(5):2167-2189.
PMID: 38505617 PMC: 10945351. DOI: 10.7150/thno.92922.